Nature 1997, 387: 299–303 CrossRefPubMed

38 Candau R, Sc

Nature 1997, 387: 299–303.CrossRefPubMed

38. Candau R, Scolnick DM, Darpino P, Ying CY, Halazonetis TD, Berger SL: Two tandem and independent sub-activation domains in the amino terminus of p53 require the adaptor complex for Selleckchem Savolitinib activity. VX-689 cost Oncogene 1997, 15: 807–816.CrossRefPubMed 39. Stock C, Kager L, Fink FM, Gadner H, Ambros PF: Chromosomal regions involved in the pathogenesis of osteosarcomas. Genes Chromosomes Cancer 2000, 28: 329–336.CrossRefPubMed 40. Zielenska M, Bayani J, Pandita A, Toledo S, Marrano P, Andrade J, Petrilli A, Thorner P, Sorensen P, Squire JA: Comparative genomic hybridization analysis identifies gains of 1p35–36 and chromosome 19 in osteosarcoma. Cancer Genet Cytogenet 2001, 130: 14–21.CrossRefPubMed 41. van Dartel M, Cornelissen PW, Redeker S, Tarkkanen M, Knuutila S, Hogendoorn PC, Westerveld A, Gomes I, Bras J, Hulsebos TJ: Amplification of 17p11.2-p12, including PMP22 , TOP3A , and MAPK7 AMN-107 cell line in high-grade osteosarcoma. Cancer Genet Cytogenet 2002, 139: 91–96.CrossRefPubMed 42. van Dartel M, Redeker S, Bras J, Kool M, Hulsebos TJ: Overexpression through amplification of genes in chromosome region 17p11.2-p12 in high-grade osteosarcoma. Cancer Genet Cytogenet 2004,

152: 8–14.CrossRefPubMed 43. Henriksen J, Aagesen TH, Maelandsmo GM, Lothe RA, Myklebost O, Forus A: Amplification and overexpression of COPS3 in osteosarcomas potentially target TP53 for proteasome-mediated degradation. Oncogene 2003, 22: 5358–5361.CrossRefPubMed 44. van Dartel M, Hulsebos TJ: Amplification and overexpression of genes in 17p11.2-p12 in osteosarcoma. Cancer Genet Cytogenet 2004, 153: 77–80.CrossRefPubMed 45. Squire JA, Pei J, Marrano P, Beheshti B, Bayani J, Lim G, Moldovan L, Zielenska M: High-resolution mapping of amplifications and deletions in pediatric osteosarcoma by use of CGH analysis of cDNA microarrays. Genes Chromosomes Cancer 2003, 38: 215–225.CrossRefPubMed 46. Tarkkanen M, Elomaa I, Blomqvist C, Kivioja AH, mafosfamide Kellokumpu-Lehtinen P, Böhling T, Valle J, Knuutila S: DNA sequence copy number

increase at 8q: a potential new prognostic marker in high-grade osteosarcoma. Int J Cancer 1999, 84: 114–121.CrossRefPubMed 47. Bayani J, Zielenska M, Pandita A, Al-Romaih K, Karaskova J, Harrison K, Bridge JA, Sorensen P, Thorner P, Squire JA: Spectral karyotyping identifies recurrent complex rearrangements of chromosomes 8, 17, and 20 in osteosarcomas. Genes Chromosomes Cancer 2003, 36: 7–16.CrossRefPubMed Competing interests The authors declare that they have no competing interests. Authors’ contributions Authors have made substantial contributions to conception and design MK and TY acquisition of data. SN, TH, TO and KS analysis, interpretation of data, organizing study. TY and supervision of research group TK”
“Introduction Bladder cancer is the second most common malignancy of the genitourinary system in both males and females [1].

Comments are closed.